195 related articles for article (PubMed ID: 22416975)
1. Histological spectrum of pulmonary manifestations in kidney transplant recipients on sirolimus inclusive immunosuppressive regimens.
Kirby S; Satoskar A; Brodsky S; Pope-Harman A; Nunley D; Hitchcock C; Pelletier R; Ross P; Nadasdy T; Shilo K
Diagn Pathol; 2012 Mar; 7():25. PubMed ID: 22416975
[TBL] [Abstract][Full Text] [Related]
2. Sirolimus-Induced Diffuse Alveolar Hemorrhage: A Case Report.
Balcan B; Simsek E; Ugurlu AO; Demiralay E; Sahin S
Am J Ther; 2016; 23(6):e1938-e1941. PubMed ID: 26849007
[TBL] [Abstract][Full Text] [Related]
3. Sirolimus-associated pulmonary toxicity.
Pham PT; Pham PC; Danovitch GM; Ross DJ; Gritsch HA; Kendrick EA; Singer J; Shah T; Wilkinson AH
Transplantation; 2004 Apr; 77(8):1215-20. PubMed ID: 15114088
[TBL] [Abstract][Full Text] [Related]
4. Patterns of pulmonary complications associated with sirolimus.
Chhajed PN; Dickenmann M; Bubendorf L; Mayr M; Steiger J; Tamm M
Respiration; 2006; 73(3):367-74. PubMed ID: 16127266
[TBL] [Abstract][Full Text] [Related]
5. Mycobacterium xenopi pulmonary infection in two renal transplant recipients under sirolimus therapy.
Thaunat O; Morelon E; Stern M; Buffet P; Offredo C; Mamzer-Bruneel MF; Kreis H
Transpl Infect Dis; 2004 Dec; 6(4):179-82. PubMed ID: 15762936
[TBL] [Abstract][Full Text] [Related]
6. Sirolimus-associated diffuse alveolar hemorrhage.
Vlahakis NE; Rickman OB; Morgenthaler T
Mayo Clin Proc; 2004 Apr; 79(4):541-5. PubMed ID: 15065619
[TBL] [Abstract][Full Text] [Related]
7. Conversion to sirolimus for chronic allograft nephropathy and calcineurin inhibitor toxicity and the adverse effects of sirolimus after conversion.
Sayin B; Karakayali H; Colak T; Sevmis S; Pehlivan S; Demirhan B; Haberal M
Transplant Proc; 2009 Sep; 41(7):2789-93. PubMed ID: 19765436
[TBL] [Abstract][Full Text] [Related]
8. Sirolimus induced dyslipidemia in tacrolimus based vs. tacrolimus free immunosuppressive regimens in renal transplant recipients.
Hakeam HA; Al-Jedai AH; Raza SM; Hamawi K
Ann Transplant; 2008; 13(2):46-53. PubMed ID: 18566560
[TBL] [Abstract][Full Text] [Related]
9. Proteinuria among primarily sirolimus treated live-donor renal transplant recipients' long-term experience.
Hamdy AF; Bakr MA; Ghoneim MA
Exp Clin Transplant; 2010 Dec; 8(4):283-91. PubMed ID: 21143093
[TBL] [Abstract][Full Text] [Related]
10. Long-term results in renal transplant patients with allograft dysfunction after switching from calcineurin inhibitors to sirolimus.
Bumbea V; Kamar N; Ribes D; Esposito L; Modesto A; Guitard J; Nasou G; Durand D; Rostaing L
Nephrol Dial Transplant; 2005 Nov; 20(11):2517-23. PubMed ID: 15985508
[TBL] [Abstract][Full Text] [Related]
11. Long-term kidney allograft function and survival in prednisone-free regimens: tacrolimus/mycophenolate mofetil versus tacrolimus/sirolimus.
Chhabra D; Skaro AI; Leventhal JR; Dalal P; Shah G; Wang E; Gallon L
Clin J Am Soc Nephrol; 2012 Mar; 7(3):504-12. PubMed ID: 22282478
[TBL] [Abstract][Full Text] [Related]
12. Sirolimus-associated diffuse alveolar hemorrhage in a renal transplant recipient on long-term anticoagulation.
Hashemi-Sadraei N; Sadrpour S; Baram D; Miller F; Nord EP
Clin Nephrol; 2007 Oct; 68(4):238-44. PubMed ID: 17969492
[TBL] [Abstract][Full Text] [Related]
13. Benefit-risk assessment of sirolimus in renal transplantation.
Kuypers DR
Drug Saf; 2005; 28(2):153-81. PubMed ID: 15691225
[TBL] [Abstract][Full Text] [Related]
14. Pulmonary alveolar proteinosis in a kidney transplant: a rare complication of sirolimus.
Kadikoy H; Paolini M; Achkar K; Suki W; Gaber AO; Anwar N; Jeroudi A; Barrios R; Abdellatif A
Nephrol Dial Transplant; 2010 Aug; 25(8):2795-8. PubMed ID: 20484303
[TBL] [Abstract][Full Text] [Related]
15. Low incidence of malignancy among sirolimus/cyclosporine-treated renal transplant recipients.
Kahan BD; Yakupoglu YK; Schoenberg L; Knight RJ; Katz SM; Lai D; Van Buren CT
Transplantation; 2005 Sep; 80(6):749-58. PubMed ID: 16210961
[TBL] [Abstract][Full Text] [Related]
16. A 12-month single arm pilot study to evaluate the efficacy and safety of sirolimus in combination with tacrolimus in kidney transplant recipients at high immunologic risk.
Lee J; Lee JJ; Kim BS; Lee JG; Huh KH; Park Y; Kim YS
J Korean Med Sci; 2015 Jun; 30(6):682-7. PubMed ID: 26028917
[TBL] [Abstract][Full Text] [Related]
17. [Pulmonary toxicity associated with sirolimus therapy in liver transplantation].
Jiménez Pérez M; Olmedo Martín R; Marín García D; Lozano Rey JM; de la Cruz Lombardo J; Rodrigo López JM
Gastroenterol Hepatol; 2006 Dec; 29(10):616-8. PubMed ID: 17198638
[TBL] [Abstract][Full Text] [Related]
18. Impact of sirolimus treatment in kidney allograft recipients with prolonged cold ischemia times: 5-year outcomes.
Boratynska M; Banasik M; Patrzalek D; Klinger M
Exp Clin Transplant; 2008 Mar; 6(1):59-66. PubMed ID: 18405247
[TBL] [Abstract][Full Text] [Related]
19. Subclinical Lesions and Donor-Specific Antibodies in Kidney Transplant Recipients Receiving Tacrolimus-Based Immunosuppressive Regimen Followed by Early Conversion to Sirolimus.
de Sandes-Freitas TV; Felipe CR; Campos ÉF; de Lima MG; Soares MF; de Franco MF; Aguiar WF; Tedesco-Silva H; Medina-Pestana JO
Transplantation; 2015 Nov; 99(11):2372-81. PubMed ID: 25929604
[TBL] [Abstract][Full Text] [Related]
20. Characteristics of sirolimus-associated interstitial pneumonitis in renal transplant patients.
Morelon E; Stern M; Israël-Biet D; Correas JM; Danel C; Mamzer-Bruneel MF; Peraldi MN; Kreis H
Transplantation; 2001 Sep; 72(5):787-90. PubMed ID: 11571438
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
